Northland Securities analyst Carl Byrnes maintained a Buy rating on GW Pharma (NASDAQ:GWPH) on Wednesday, setting a price target of $150, which is approximately 30.54% above the present share price of $114.91.
Byrnes expects GW Pharma to post earnings per share (EPS) of $0.00 for the fourth quarter of 2020.
The current consensus among 9 TipRanks analysts is for a Strong Buy rating of shares in GW Pharma, with an average price target of $157.
The analysts price targets range from a high of $183 to a low of $121.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $137.05 million and a net profit of -$12.72 million. The company's market cap is $3.58 billion.
According to TipRanks.com, Northland Securities analyst Carl Byrnes is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -12.2% and a 31.03% success rate.
GW Pharmaceuticals (OTC:GWPRF) Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It offers its cannabinoid product, Epidiolex oral solution CV, a pharmaceutical formulation of cannabidiol (CBD) focusing on the treatment of seizures associated with tuberous sclerosis complex. The company was founded by Geoffrey William Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.